Health Catalyst, Inc.

NASDAQ:HCAT

Medical - Healthcare Information Services

Healthcare
$1.29 -1.98%

-$0.04 today

Market cap
$98.24M
Beta
1.66
P/E (TTM)
-0.5
EPS (TTM)
-$3.65
52W Low $0.96High $4.13

Volume 0.27M

Average 1.24M

HCAT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Health Catalyst, Inc.NASDAQ: HCAT

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $4.94M (cash outflow) rose 637.6% year over year, ahead of the -31.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 1710.3% from the prior quarter. Over 3 fiscal years it compounded at -61.8% a year.

Context

  • Capital expenditures amounted to 0.3% of revenue in FY2025, down 5.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +637.6% holds above the trailing-twelve-month pace of -31.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.94M+1710.3% QoQ
Last fiscal yearDec 2025
-$968K-94.1% YoY
LTMMar 2026
-$9.79M-31.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+637.6%——
1 year-94.1%——
3-year CAGR-61.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(968K) USD
Year-over-year change
+94.1%

Capital Expenditures vs competitors

How HCAT compares with its peers on the latest reported figures

  • HCAT's LTM Mar 2026 capital expenditures of $9.79M is the largest of the 11 companies compared; the peer median is $317.5K.
  • Its year-over-year change of -31.3% is the 5th highest of 9, against a peer median of -31.1%.
  • Capital expenditures amounts to 3.2% of revenue for HCAT, versus a peer median of 1.2%.
HCAT Competitors Peer median
Capital Expenditures for HCAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCATHealth Catalyst, Inc.LTM Mar 2026$9.79M -31.3%-61.8%3.2%
NNOXNano-X Imaging Ltd.LTM Dec 2025$4.45M +61.0%-16.3%34.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.77M -93.4%+82.4%2.6%
OMOutset Medical, Inc.LTM Mar 2026$740K +8.7%-54.2%0.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$561K +42.7%-6.1%1.7%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$389K -91.5%-40.5%3.5%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$246K -70.9%-68.9%109.3%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$73K +113.6%—0.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$20K -96.2%-71.9%0.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$9K —-88.8%0.1%
HSDTSolana CompanyLTM Mar 2026$0 —+1281.0%0.0%
Peer median (excluding HCAT) $317.5K-31.1%-40.5%1.2%

Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(153.21M)(137.4M)(118.15M)(69.5M)(177.97M)
Depreciation & Amortization37.53M48.3M42.22M41.43M50.5M
Deferred Income Tax(7.13M)(4.52M)8K77K81K
Stock-Based Compensation65.15M72.1M55.76M40.13M27.01M
Change in Working Capital4.62M(13.91M)(13.67M)(660K)(15.11M)
Accounts Receivables102K788K(13.66M)4.28M(1.81M)
Inventory(8.33M)0000
Accounts Payables5.2M(4.7M)4.87M5.58M(11.51M)
Other Working Capital7.64M(9.99M)(4.88M)(10.52M)(1.79M)
Other Non-Cash Items29.93M162K750K3.09M116.22M
Operating Cash Flow(23.12M)(35.27M)(33.08M)14.56M731K
Capital Expenditures(18.47M)(17.41M)(14.31M)(16.4M)(968K)
Acquisitions (Net)(46.76M)(27.85M)(11.39M)(80.28M)(41.11M)
Purchases of Investments(261.36M)(308.96M)(290.84M)(168.31M)(65.13M)
Sales of Investments186.89M315.17M336.8M242.07M163.95M
Other Investing Activities22K(15.22M)(13.04M)(14.77M)(20.54M)
Investing Cash Flow(139.68M)(39.02M)20.29M(22.9M)36.19M
Debt Repayment000151.32M(232.29M)
Common Stock Issued245.18M002.58M1.51M
Common Stock Repurchased0(8.39M)(1.81M)0(5M)
Dividends Paid00000
Other Financing Activities18.9M5.78M4.54M(2.15M)0
Financing Cash Flow264.08M(2.61M)2.73M151.75M(235.78M)
Effect of Forex Changes(10K)(11K)21K(34K)27K
Net Change in Cash101.27M(76.92M)(10.04M)143.37M(198.83M)
Free Cash Flow(41.59M)(52.68M)(47.39M)(1.84M)(237K)

Health Catalyst, Inc.

NASDAQ:HCAT

Intrinsic Alpha fair value

Locked

Current Price

$1.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.